Company / Financials
Editas Medicine, Inc. Financials
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$32.3M
FY2025 · +63.9% YoY
Net Income
-$237.1M
FY2025 · -7.6% YoY
Profit Margin
-733.7%
FY2025 · net income / revenue
ROE
-176.6%
FY2025 · return on equity
Total Assets
$186.5M
FY2025
Total Debt
$53.6M
0.40x debt/equity
Equity
$134.3M
FY2025
ROA
-127.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$32.3M+63.9% YoYNet Income HistoryProfit after all expenses and taxes-$237.1M-7.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$251.2M-11.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$72.0M+1.8% YoYR&D Expense HistoryResearch and development spending$199.2M+13.9% YoYInterest Expense HistoryCost of borrowing and debt obligations$2.2M+2.9% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$2.88+10.3% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.88+10.3% YoYShares Outstanding HistoryWeighted average diluted shares outstanding82.7M+1.2% YoY